MedTrace Logo

Study of Atorvastatin Dose Dependent Reduction of Proteinuria

NCT00768638 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2015-04-29

No results posted yet for this study

Summary

Randomized controlled double blind study of parallel groups to evaluate the comparative effects of low-dose of atorvastatin on proteinuria in patients with stage 3 or 4 chronic kidney disease.

Conditions

Interventions

DRUG

Atorvastatin

Atorvastatin 10mg 1co id (10mg active) Placebo 40mg 1co id (40mg inactive)

DRUG

Atorvastatin

Atorvastatin 40mg 1co id (40mg active) Placebo 10mg 1co id (10mg inactive)

Sponsors & Collaborators

  • Laval University

    lead OTHER

Principal Investigators

  • Mohsen Agharazii, MD · Laval University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2014-05-31
Completion
2014-06-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00768638 on ClinicalTrials.gov